Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro

The company uses iPS cells to develop treatments for diseases relating to the kidney

Max Healthcare posts Q2 FY25 consolidated PAT at Rs. 281.81 Cr

Max Healthcare Institute has reported total income of Rs. 1,748.30 crores during the period ended September 30, 2024

Apollo Hospitals reports Q2 FY25 consolidated PAT at Rs. 378.8 Cr

Apollo Hospitals Enterprise has reported total income of Rs. 5,627.5 crores during the period ended September 30, 2024

Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr

US Generics grew 5% to Rs. 467 Crores for the quarter

Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr

Revenue growth was fueled by higher volumes and contributions from both existing and new centres

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25

Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr

Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.

Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility

The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities

Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024

Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion

Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion

Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr

Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24

Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies

Gland Pharma posts Q2 FY25 consolidated profit at Rs. 163.53 Cr

The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024

AbbVie and EvolveImmune Therapeutics collaborate to develop next-generation cancer biotherapeutics

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer

Emcure Pharma forms subsidiary to strengthen dermatology portfolio

The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore

Yatharth Hospitals acquires 60% stake in 400-bedded hospital in Faridabad for Rs. 91 Cr

Briefs: Sun Pharmaceutical Industries and Biocon Biologics

The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI

MilliporeSigma invests US$ 76 million to expand ADC manufacturing in North America

Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America

AbbVie to acquire Aliada Therapeutics

Strengthening focus in Alzheimer's disease and neuroscience pipeline